Sanofi secures EU approval for subcutaneous Sarclisa formulation and reports other drug development news
Sanofi has received European Union approval for a subcutaneous formulation of its cancer drug Sarclisa, delivered via a portable autoinjector. The company also announced other updates regarding its drug development pipeline.
Sanofi has gained European Union approval for a subcutaneous (SC) formulation of its cancer treatment Sarclisa. The drug, intended for specific cancers, will be delivered using a portable autoinjector, marking a first for cancer therapies administered this way.
The company also noted that venglustat has received priority review status in the United States for the treatment of Gaucher disease type 3. Additionally, Cenrifki (tolebrutinib) received a positive recommendation for EU approval for treating secondary progressive multiple sclerosis.
Furthering access to treatments, Sanofi has also strengthened its collaboration with Biogen to accelerate the diagnosis of rare diseases in France through the accelRare initiative. The company also reported its first-quarter financial results, demonstrating double-digit growth in revenue and earnings per share.
Recent developments also include the US approval of Dupixent as a biologic therapy for children with uncontrolled chronic spontaneous urticaria, and the US approval of Tzield to delay the onset of stage 3 type 1 diabetes in young children.